论文部分内容阅读
目的:以注射用哌拉西林/他唑巴坦(8:1)为对照,评价注射用哌拉西林/舒巴坦(2:1)治疗呼吸和泌尿系统中、重度细菌性感染的有效性和安全性。方法:采用多中心、随机、双盲、平行对照的试验方法,实验组和对照组均采用每次4.0 g(以哌拉西林含量计),每日2次,疗程7~10d的治疗方案。试验组和对照组的临床可评价病例为100例和103例,细菌学疗效评价病例为90和81例,药物安全性评价例数均为105例。结果:试验组和对照组的临床有效率分别为95.0%和91.3%;细菌清除率分别为90.0%和95.1%;药物不良反应发生率分别为6.8%和4.8%;经统计学检验,以上结果试验药和对照药间的差异均无统计学意义(P>0.05)。结论:哌拉西林/舒巴坦是治疗呼吸、泌尿系统中、重度细菌性感染的安全、有效药物。
OBJECTIVE: To evaluate the effectiveness of piperacillin / sulbactam (2: 1) for the treatment of severe bacterial infections in the respiratory and urinary systems by piperacillin / tazobactam (8: 1) And safety. Methods: A multicenter, randomized, double-blind, parallel-controlled trial was conducted. The experimental group and the control group received 4.0 g (taking piperacillin content) twice daily for 7-10 days. The clinically evaluable cases in trial and control groups were 100 cases and 103 cases, the bacteriological efficacy evaluation cases were 90 and 81 cases, and the drug safety evaluation cases were all 105 cases. Results: The clinical effective rates of the experimental group and the control group were 95.0% and 91.3% respectively; the bacterial clearance rates were 90.0% and 95.1% respectively; the adverse drug reactions were 6.8% and 4.8% respectively. The statistical analysis showed that the above results There was no significant difference between test drug and control drug (P> 0.05). Conclusion: Piperacillin / sulbactam is a safe and effective drug for the treatment of severe bacterial infections in respiratory and urinary system.